Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Excellent results obtained in AML patients receiving Maxamine plus IL-2

Dec. 9, 1998

U.S. patent covers Coulter's antibody therapy for B-cell lymphoma

Dec. 9, 1998

Biomira initiates pivotal phase III trial of Theratope vaccine

Dec. 7, 1998

Maxamine Therapy enters phase II trial for late-stage RCC

Dec. 4, 1998

Coulter and SB enter agreement to develop and commercialize I-131 anti-B1 antibody

Dec. 4, 1998

Enrollment completed in phase I Biomira lung cancer vaccine trial

Dec. 4, 1998

MDX-210 demonstrates antitumor activity in phase II studies

Dec. 4, 1998

Vical provides clinical update of Leuvectin in treatment of prostate cancer

Dec. 2, 1998

Neurocrine Biosciences advances development of NBI-3001

Nov. 30, 1998

Cell Genesys broadens GVAX trials program in prostate cancer

Nov. 30, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...